Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

NCT07729046 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT07729046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2027
Completion date
June 30, 2035
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er+, her2-, metastatic breast cancer, metastatic invasive breast cancer, resistant breast cancer